Pharvaris (PHVS) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free PHVS Stock Alerts $22.77 +1.52 (+7.15%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePharvaris' (PHVS) "Overweight" Rating Reaffirmed at Morgan Stanleyamericanbankingnews.com - April 23 at 3:32 AMPharvaris (NASDAQ:PHVS) Shares Up 8%marketbeat.com - April 22 at 4:46 PMMorgan Stanley Reiterates "Overweight" Rating for Pharvaris (NASDAQ:PHVS)marketbeat.com - April 22 at 2:24 PMPharvaris Forecasted to Earn Q4 2024 Earnings of ($0.54) Per Share (NASDAQ:PHVS)americanbankingnews.com - April 19 at 2:46 AMPharvaris (NASDAQ:PHVS) Price Target Cut to $34.00 by Analysts at Morgan Stanleyamericanbankingnews.com - April 16 at 4:50 AMPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatmentmarkets.businessinsider.com - April 15 at 9:41 AMPharvaris (NASDAQ:PHVS) Forecasted to Earn FY2028 Earnings of $1.43 Per Shareamericanbankingnews.com - April 15 at 1:52 AMBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financialsmarkets.businessinsider.com - April 12 at 8:13 AMPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - April 12 at 8:13 AMPharvaris appoints new CFO to bolster financial strategyinvesting.com - April 12 at 3:12 AMPharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - April 11 at 7:00 AMBuy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial Stabilitymarkets.businessinsider.com - April 11 at 7:00 AMPHVS Pharvaris N.V.seekingalpha.com - April 11 at 1:59 AMPHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023investorplace.com - April 10 at 11:09 PMPharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - April 10 at 4:10 PMPharvaris Appoints David Nassif, J.D., as Chief Financial Officerglobenewswire.com - April 10 at 4:08 PMPharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conferenceglobenewswire.com - April 4 at 6:50 AMPharvaris (NASDAQ:PHVS) Shares Gap Down to $22.15marketbeat.com - April 3 at 1:36 PMPharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congressesglobenewswire.com - March 18 at 6:50 AMPharvaris to Present Deucrictibant Clinical Data at Upcoming Congressesglobenewswire.com - March 6 at 6:50 AMPharvaris to Participate in the Leerink Global Biopharma Conference 2024globenewswire.com - March 5 at 6:50 AMPharvaris (NASDAQ:PHVS) Short Interest Down 49.0% in Februarymarketbeat.com - February 29 at 8:41 AMPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE Treatmentmarkets.businessinsider.com - February 26 at 5:45 AMPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97msn.com - February 25 at 2:33 AMPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meetingfinance.yahoo.com - February 22 at 9:45 AMPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meetingglobenewswire.com - February 22 at 6:50 AMPharvaris Announces Extraordinary Meeting of Shareholdersfinance.yahoo.com - February 16 at 7:48 AMPharvaris Announces Extraordinary Meeting of Shareholdersglobenewswire.com - February 16 at 6:50 AMWedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)markets.businessinsider.com - February 14 at 6:25 PMPharvaris to Present at the WSAAI Annual Meeting 2024finance.yahoo.com - January 26 at 10:51 PMBuy Rating Affirmed for Pharvaris with Increased Price Target Following FDA Regulatory Advancesmarkets.businessinsider.com - January 24 at 5:30 AMPharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Programfinance.yahoo.com - January 23 at 2:29 PMPharvaris N.V.: Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacksfinanznachrichten.de - January 22 at 8:29 AMPharvaris rises as FDA lifts hold on hereditary angioedema candidatemsn.com - January 22 at 8:29 AMPharvaris Says FDA Lifts Clinical Hold On IND For Deucrictibant For Treatment Of HAE Attacksmarkets.businessinsider.com - January 22 at 8:29 AMPharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacksfinance.yahoo.com - January 22 at 8:29 AMPharvaris: Digging Deep For Sufficient Market Sizeseekingalpha.com - January 17 at 7:45 AMPositive Clinical Trials and Strong Financial Position Support Buy Rating for Pharvarismarkets.businessinsider.com - January 9 at 8:48 PMBuy Rating Affirmed for Pharvaris Amid Anticipated Clinical Updates and Positive Trial Prospectsmarkets.businessinsider.com - January 6 at 8:13 AMPharvaris N.V.: Pharvaris Provides Business Update and Outlines 2024 Strategic Prioritiesfinanznachrichten.de - January 5 at 1:02 PMPharvaris Provides Business Update and Outlines 2024 Strategic Prioritiesfinance.yahoo.com - January 5 at 8:01 AMPharvaris (PHVS) Price Target Increased by 38.65% to 32.93msn.com - December 17 at 12:17 AMAnalysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Pharvaris (PHVS) and Tourmaline Bio (TRML)markets.businessinsider.com - December 11 at 5:32 PMPharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last weekfinance.yahoo.com - December 11 at 7:31 AMPharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023tmcnet.com - December 8 at 7:22 PMPharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023finance.yahoo.com - December 8 at 7:22 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pharvaris (PHVS), Veeva Systems (VEEV) and UnitedHealth (UNH)markets.businessinsider.com - December 7 at 6:17 PMBioCryst falls after Pharvaris win for hereditary angioedema drugmsn.com - December 6 at 2:32 PMTurnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacksmarkets.businessinsider.com - December 6 at 2:32 PMWhy Is Pharvaris (PHVS) Stock Up 36% Today?investorplace.com - December 6 at 12:01 PM Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. PHVS Media Mentions By Week PHVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼0.610.41▲Average Medical News Sentiment PHVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼82▲PHVS Articles Average Week Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Context Therapeutics News Grifols News LAVA Therapeutics News Mainz Biomed News NLS Pharmaceutics News Tiziana Life Sciences News Aclarion News Alpha Tau Medical News American Oncology Network News Artelo Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
